New drug ACT500 targets dual liver disease in early trial
NCT ID NCT07589400
First seen May 19, 2026 · Last updated May 19, 2026
Summary
This early-stage study tests a new oral drug called ACT500 in 24 adults who have both fatty liver disease and chronic hepatitis B. The main goal is to check the drug's safety and how the body processes it. Participants will take the drug once daily for a short time, and researchers will monitor side effects and drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Friendship Hospital, Capital Medical University
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Contact
-
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, China
Contact
-
Xiamen Hospital of Traditional Chinese Medicine
Xiamen, China
Contact
Conditions
Explore the condition pages connected to this study.